Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Ann Oncol
; 27(11): 2046-2052, 2016 11.
Article
in En
| MEDLINE
| ID: mdl-27502725
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antibodies, Monoclonal, Humanized
/
Bevacizumab
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
Aspects:
Patient_preference
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Ann Oncol
Year:
2016
Document type:
Article